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Impact of ticagrelor administration 
strategy on its pharmacokinetics and 
pharmacodynamics in patients with 
unstable angina pectoris: a protocol of 
a randomized study
ABSTRACT
Introduction. Dual antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor constitutes an essen-
tial part of the management of patients with acute coronary syndromes (ACS). Based on the favorable 
results of the PLATO trial, ticagrelor is currently recommended as the first line P2Y12 receptor inhibitor in 
a broad spectrum of ACS patients. According to the recently published data, several conditions, including 
concurrent analgesia with morphine and clinical presentation as an ACS, may alter ticagrelor absorption 
and its antiplatelet effect. Therefore, the goal of the present study was to investigate pharmacokinetics 
and pharmacodynamics of new ticagrelor administration strategies aimed to overcome limitations of the 
standard ticagrelor loading regimen.
Methods/design. The study is designed as a phase IV, single center, randomized, investigator-initiated, 
parallel-group, open-label, interventional study comparing the influence of various ticagrelor administration 
strategies on its pharmacokinetics and pharmacodynamics. Patients with unstable angina pectoris will 
be randomized in a 1:1:1 ratio into one of three arms, each receiving a 180 mg ticagrelor loading dose 
(LD). Ticagrelor administration strategies comprise: 1) pulverized ticagrelor administered sublingually, 
2) pulverized ticagrelor in 10 mL suspension in tap water administered orally and 3) integral ticagrelor 
tablets administered orally. An internal pilot study including 30 (10 in each of the arms) is planned in order 
to determine the final sample size. The primary endpoint of the trial is time (tmax) required for ticagrelor 
and its active metabolite AR-C124900XX to reach maximum plasma concentration within time frame of six 
hours after administration of ticagrelor LD. The secondary endpoints include ticagrelor and AR-C124900XX 
maximum plasma concentration, area under the plasma concentration-time curve for ticagrelor and 
AR-C124900XX (AUC 0–6h) and platelet reactivity assessed with Multiple Electrode Aggregometry using 
the Multiplate™ Analyzer prior to and within time frame of six hours following ticagrelor LD.
Discussion. This study is expected to provide essential evidence-based data on the impact of ticagrelor 
administration strategy on its pharmacokinetics and pharmacodynamics in patients with unstable angina 
pectoris. Hopefully, based on its results, further clinical outcome-powered trials on new ticagrelor admin-
istration strategies will be designed and conducted.
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Introduction
Based on the guidelines of the European Society 
of Cardiology (ESC), antiplatelet therapy comprising 
aspirin and a  P2Y12 receptor inhibitor is a  recom-
mended regimen for patients with acute coronary 
syndromes (ACS) [1, 2]. Clinical advantages of either 
ticagrelor or prasugrel over clopidogrel have been 
proven in large clinical trials, such as the TRial to 
assess Improvement in Therapeutic Outcomes by 
optimizing platelet inhibitioN with prasugrel-Throm-
bolysis In Myocardial Infarction 38 (TRITON-TIMI 38) 
or PLATelet inhibition and patient Outcomes (PLATO) 
studies, thus making these agents preferable 
P2Y12 receptor inhibitors in ACS patients [3–9]. 
Importantly, ticagrelor is currently recommended as the 
first line P2Y12 receptor inhibitor in a broad spectrum of 
ACS patients, also in subjects managed conservatively 
and in patients who are likely to undergo coronary artery 
bypass surgery, in the subsets where prasugrel should 
be avoided [1].
It is believed that adequate platelet inhibition is 
crucial during percutaneous coronary intervention 
(PCI) and in the periprocedural period, particularly in 
patients undergoing coronary stenting, because im-
plantation of thrombogenic stent into the thrombotic 
lesion exposes patients to the risk of stent thrombo-
sis, a potentially fatal complication. Therefore, routine 
immediate administration of antiplatelet agents, just 
after making the initial diagnosis, is recommended 
in all ACS patients with the exception of prasugrel, 
which should not be given in subjects with non-ST 
elevation ACS until coronary angiography is com-
pleted [1].
Notably, morphine is considered a drug of choice 
for chest pain alleviation in patients presenting with 
acute myocardial infarction [2]. Nevertheless, based 
on the available data, morphine, an opioid anal-
gesic, may lead to decreased clopidogrel plasma 
concentration and its attenuated antiplatelet action 
if both drugs are administered simultaneously [10]. 
Additionally, our recent randomized study indicated 
that morphine delays and attenuates ticagrelor expo-
sure and action in patients with myocardial infarction 
[11–13]. Similarly, morphine was also demonstrat-
ed to decrease ticagrelor concentrations, but not 
its antiplatelet effects, in healthy volunteers [14]. 
Besides morphine co-administration, other clinical 
conditions (e.g. clinical presentation with an ACS, 
particularly ST-segment elevation myocardial in-
farction (STEMI), concomitant cardiogenic shock, 
unconsciousness, incapability to swallow, malab-
sorption, therapeutic hypothermia) may reduce 
absorption of P2Y12 receptor inhibitors and/or their 
antiplatelet action [15–18]. 
Interestingly, Zafar et al. demonstrated higher bio-
availability of crushed vs. integral clopidogrel tablets 
in healthy volunteers [19]. Similarly, administration of 
pulverized vs. integral ticagrelor tablets was associated 
with increased antiplatelet effect in STEMI patients in 
the Mashed Or Just Integral pill of TicagrelOr (MOJITO) 
study [20].
These reports provide a solid rationale for new tica-
grelor administration strategies, which may overcome 
limitations of the standard ticagrelor loading regimen. 
Thus, we designed a study evaluating differences in 
ticagrelor pharmacokinetics and pharmacodynamics 
in patients who received pulverized tablets either orally 
or sublingually in comparison with conventional oral 
administration of integral tablets. 
Methods
The trial is designed as a phase IV, single center, 
randomized, investigator-initiated, parallel-group, 
open-label, interventional study aimed to evaluate the 
influence of ticagrelor administration strategies on its 
pharmacokinetics and pharmacodynamics in patients 
hospitalized for unstable angina pectoris. The protocol 
of the study was approved by The Ethics Committee 
of Nicolaus Copernicus University in Toruń, Ludwik 
Rydygier Collegium Medicum in Bydgoszcz (approval 
number KB 540/2015). The study is conducted in compli-
ance with the regulations established in the Declaration 
of Helsinki. Each participant needs to sign a  written 
informed consent before enrollment into the trial. The 
eligibility criteria for enrollment into the study include 
male and non-pregnant female patients in the age range 
of 18–80 years, diagnosed with unstable angina pectoris 
whose mortality risk score was assessed < 140 points 
according to GRACE Score, who signed a  written 
consent for coronary angiography PCI, if needed. Key 
exclusion criteria include ongoing (or terminated within 
14 preceding days) treatment with any P2Y12 receptor 
inhibitor, treatment with oral or parenteral anticoag-
ulants, history of intracranial hemorrhage or recent 
(defined as last 30 days) gastrointestinal hemorrhage, 
coagulation disorders, severe chronic pulmonary disor-
ders, second or third degree atrioventricular block, Killip 
class III or IV on the point of screening. The full list of 
inclusion and exclusion criteria is presented in Table 1.
The study site is The Department of Cardiology, 
Antoni Jurasz University Hospital in Bydgoszcz, Po-
land. Patients diagnosed with unstable angina pectoris 
who signed the informed consent, are subsequently 
randomized in a 1:1:1 manner into one of three arms 
each receiving a 180 mg ticagrelor loading dose (LD). 
Ticagrelor administration strategies comprise: 1) pulver-
ized ticagrelor administered sublingually, 2) pulverized 
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Table 1. The complete list of inclusion and exclusion criteria used in the study
Inclusion criteria Exclusion criteria
Provision of informed consent prior to any study 
specific procedures
Clinical diagnosis of unstable angina
Male or non-pregnant female, aged 18–80
Provision of informed consent for angiography  
and percutaneous coronary intervention (PCI)
GRACE score < 140 pts
Treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within  
14 days before the study enrollment
Hypersensitivity to ticagrelor
Current treatment with oral anticoagulant or chronic therapy with low- 
-molecular-weight heparin
Active bleeding
History of intracranial hemorrhage
Recent gastrointestinal bleeding (within 30 days)
History of coagulation disorders
Platelet count less than <100 × 10^3/mcL
Hemoglobin concentration less than 10.0 g/dL
History of moderate or severe hepatic impairment
History of major surgery or severe trauma (within 3 months)
Patients considered by the investigator to be at risk of bradycardic events
Second or third degree atrioventricular block during screening for eligibility
History of asthma or severe chronic obstructive pulmonary disease
Patient requiring dialysis
Manifest infection or inflammatory state
Killip class III or IV during screening for eligibility
Respiratory failure
History of severe chronic heart failure (NYHA class III or IV)
Concomitant therapy with strong CYP3A inhibitors (ketoconazole, 
itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, 
ritonavir, saquinavir, nelfinavir, indinavir, atazanavir) or strong CYP3A 
inducers (rifampicin, phenytoin, carbamazepine, dexamethasone, 
phenobarbital) within 14 days and during study treatment
Body weight below 50 kg
ticagrelor in 10 mL suspension in tap water administered 
orally and 3) integral ticagrelor tablets administered 
orally. Randomization is conducted using Random 
Allocation Software version 1.0. Coronary angiography 
is performed at least six hours after the enrollment into 
the trial, after completing the blood sample collecting 
schedule. The study results will be reported in line with 
the CONSORT statement [21, 22]. The scheme of the 
study is presented in Figure 1.
Endpoints
The primary endpoint of the trial is time (tmax) 
required for ticagrelor and its active metabolite 
AR-C124900XX to reach maximum plasma concentration 
within time frame of six hours after administration of tica-
grelor LD. The secondary endpoints include ticagrelor 
and AR-C124900XX maximum plasma concentration, 
area under the plasma concentration-time curve for 
ticagrelor and AR-C124900XX (AUC 0–6h) and platelet 
reactivity assessed with Multiple Electrode Aggregom-
etry (MEA) using the MultiplateTM Analyzer prior to and 
within time frame of six hours following ticagrelor LD. 
All the study endpoints together with details regarding 
sampling are listed in Table 2.
Blood sample collection
Blood collection using an intravenous catheter is 
scheduled directly prior to ticagrelor LD and 15, 30, 
45, 60, 120, 180, 240, 360 minutes following LD. Blood 
collection is performed by cardiology intensive care 
nurses and is supervised by the physician responsible 
for previous eligibility screening for each patient. 
Pharmacokinetics and 
pharmacodynamics 
Pharmacokinetic assessments of all blood samples 
obtained according to the schedule are performed in The 
Department of Medicinal Chemistry, Nicolaus Copernicus 
University, Ludwik Rydygier Collegium Medicum in Byd-
goszcz. Concentration of ticagrelor and its active metabolite 
(AR-C124910XX) are determined with liquid chromatography 
tandem mass spectrometry. Pharmacodynamic measure-
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Table 2. The list of study endpoints
Primary endpoint of the study Secondary endpoints of the study
Time to maximum  
concentration (tmax)  
for ticagrelor  
and AR-C124900XX  
[Time frame: 6 hours] 
Maximum ticagrelor and AR-C124900XX concentration [Time frame: 6 hours]
Area under the plasma concentration-time curve for ticagrelor (AUC 0–6 h) 
[Time frame: pre-dose and 15 min, 30 min, 45 min, 1, 2, 3, 4, 6 hours post dose] 
Area under the plasma concentration-time curve for AR-C124900XX (AUC 0–6h) 
[Time frame: pre-dose and 15 min, 30 min, 45 min, 1, 2, 3, 4, 6 hours post dose]
Platelet reactivity assessed by Multiple Electrode Aggregometry [Time frame: pre-dose and 
30 min, 1, 2, 3, 4, 6 hours post dose]
Figure 1. The schematic protocol of the study
ments for the sake of the trial are performed using Multiple 
Electrode Aggregometry (MEA; the MultiplateTM Analyzer, 
Roche Diagnostics International Ltd, Rotkreuz, Switzerland). 
MEA will be used in all enrolled participants. Pharmacoki-
netic and pharmacodynamic analyzes are performed by 
blinded skilled investigators. Both methods have been 
described in details previously [11, 12, 23–25].
Pilot study
We plan to perform an internal pilot study including 
30 (10 in each of the arms) in order to determine the 
final sample size.
Safety of the trial
The study population is limited only to patients 
diagnosed with unstable angina pectoris, whose 
mortality risk is low or intermediate, as estimated by 
the GRACE score (< 140 points). Moreover, all par-
ticipants receive medications of all other groups rec-
ommended by the ESC guidelines for the ACS man-
agement, e.g. aspirin, statins, beta-blockers, angio-
tensin converting enzyme inhibitors or angiotensin II 
receptor inhibitors. Every case of patient’s condition 
deterioration leading to the necessity of immediate 
coronary angiography will result in the discontinu-
ation of that patient’s participation in the trial so as 
to ensure appropriate therapy. For the entire hospi-
talization period, the study participants will receive 
ticagrelor maintenance dose of 90 mg twice daily with 
the strong recommendation to continue therapy with 
ticagrelor after discharge. Ticagrelor may be replaced 
with clopidogrel (a 600 mg clopidogrel loading dose 
will be administered) in patients unable to continue 
such treatment, mainly due to financial reasons, on 
the day of discharge from The Department of Car-
diology. 
Discussion
This study is expected to provide essential 
evidence-based data on the impact of ticagrelor 
administration strategies on its pharmacokinetics 
and pharmacodynamics in patients with unstable 
angina pectoris. Hopefully, based on its results, 
further clinical outcome-powered trials on new ti-
cagrelor administration strategies will be designed 
and conducted.
The study status
The study is currently recruiting participants. It was 
registered in the ClinicalTrials.gov database and re-
ceived identifier NCT02612116. 
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